<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–52" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–52/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–52/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_52"><akn:num>379j–52</akn:num><akn:heading>Authority to assess and use biosimilar biological product fees</akn:heading><akn:content><akn:p>§ 379j–52. Authority to assess and use biosimilar biological product fees(a) Types of feesBeginning in fiscal year 2023, the Secretary shall assess and collect fees in accordance with this section as follows:(1) Biosimilar biological product development program fees(A) Initial biosimilar biological product development fee(i) In generalEach person that submits to the Secretary a meeting request described under clause (ii) or a clinical protocol for an investigational new drug protocol described under clause (iii) shall pay for the product named in the meeting request or the investigational new drug application the initial biosimilar biological product development fee established under subsection (c)(5).


(ii) Meeting requestThe meeting request described in this clause is a request for a biosimilar biological product development meeting for a product.


(iii) Clinical protocol for INDA clinical protocol for an investigational new drug protocol described in this clause is a clinical protocol consistent with the provisions of section 355(i) of this title, including any regulations promulgated under section 355(i) of this title, (referred to in this section as “investigational new drug application”) describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for a product.


(iv) Due dateThe initial biosimilar biological product development fee shall be due by the earlier of the following:(I) Not later than 7 days after the Secretary grants a request for a biosimilar biological product development meeting.

(II) The date of submission of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application.


(v) Transition ruleEach person that has submitted an investigational new drug application prior to July 9, 2012, shall pay the initial biosimilar biological product development fee by the earlier of the foll</akn:p></akn:content><akn:subsection eId="subsec_379j_52_a"><akn:num>(a)</akn:num><akn:heading>Types of fees</akn:heading><akn:content><akn:p>(a) Types of fees Beginning in fiscal year 2023, the Secretary shall assess and collect fees in accordance with this section as follows:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_b"><akn:num>(b)</akn:num><akn:heading>Fee revenue amounts</akn:heading><akn:content><akn:p>(b) Fee revenue amounts</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_c"><akn:num>(c)</akn:num><akn:heading>Adjustments; annual fee setting</akn:heading><akn:content><akn:p>(c) Adjustments; annual fee setting</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_d"><akn:num>(d)</akn:num><akn:heading>Application fee waiver for small business</akn:heading><akn:content><akn:p>(d) Application fee waiver for small business</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_e"><akn:num>(e)</akn:num><akn:heading>Effect of failure to pay fees</akn:heading><akn:content><akn:p>(e) Effect of failure to pay fees A biosimilar biological product application or supplement submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_f"><akn:num>(f)</akn:num><akn:heading>Crediting and availability of fees</akn:heading><akn:content><akn:p>(f) Crediting and availability of fees</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_g"><akn:num>(g)</akn:num><akn:heading>Collection of unpaid fees</akn:heading><akn:content><akn:p>(g) Collection of unpaid fees In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_h"><akn:num>(h)</akn:num><akn:heading>Written requests for waivers and returns; disputes concerning fees</akn:heading><akn:content><akn:p>(h) Written requests for waivers and returns; disputes concerning fees To qualify for consideration for a waiver under subsection (d), or for the return of any fee paid under this section, including if the fee is claimed to have been paid in error, a person shall submit to the Secretary a written request justifying such waiver or return and, except as otherwise specified in this section, such written request shall be submitted to the Secretary not later than 180 days after such fee is due. A request submitted under this paragraph shall include any legal authorities under which the request is made.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_52_i"><akn:num>(i)</akn:num><akn:heading>Construction</akn:heading><akn:content><akn:p>(i) Construction This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in the process of the review of biosimilar biological product applications, be reduced to offset the number of officers, employees, and advisory committees so engaged.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>